A Prescription To Treat Reputational Ills In Pharma Cos.

Law360, New York (February 1, 2013, 12:29 PM EST) -- Over the past few years, the compliance practices and reputations of pharmaceutical companies have clearly been under increasing scrutiny. Recent settlements of government investigations into industry practices have netted the U.S. Department of Justice's record-setting fines, many involving off-label sales and marketing schemes[1],[2].

Addressing such wrongdoing is a responsibility shared by many in an organization, but at the end of the day, the governing board is held ultimately accountable. To fulfill this duty, board members must oversee and ensure the effectiveness of the corporate ethics and...
To view the full article, register now.